Results for: Quiz 1z0-076 - Oracle Database 19c: Data Guard Administration Marvelous Reliable Exam Sample 🔡 Download ▷ 1z0-076 ◁ for free by simply searching on “ www.pdfvce.com ” 😙1z0-076 Valid Test Tips

SPMS pathogenesis and treatment

November 14, 2022

…on in whole-brain atrophy with siponimod versus placebo was 49% at year 1 (-0.23 vs. -0.45), and 31% at year 2 (-0.62 vs. -0.92). Relative reduction in cortical GM volume loss with siponimod versus placebo was 102% at 1 year (+0.01 vs. -0.60), and 63% at 2 years (-0.39 vs. -1.04). There were also significant reductions in thalamic volume loss at both time points (50% year 1, 42% at year 2). Moreover, siponimod improved brain tissue integrity and r…

ECTRIMS 2022 SLIDE DECK

November 10, 2022

…h Dr. Daniel Selchen. The slide deck is open access, and no permissions are required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire NEW An edited version of the webinar featuring Dr. Daniel Selchen is now available for viewing:…

ECTRIMS 2022 HIGHLIGHTS – SATURDAY, OCTOBER 29 EDITION

October 29, 2022

…in the first three months after stopping fingolimod or natalizumab. A five-year follow-up study in the Netherlands investigated disease reactivation in 130 patients (mean age 45 years) who stopped taking a platform DMT (Coerver et al. ECTRIMS 2022; P302). Overall, 47.7% of patients had new MRI activity and 30.8% experienced a relapse after discontinuing treatment; 22.3% restarted treatment after a median 17 months. Patients aged 45-55 years had a…

ECTRIMS 2022 HIGHLIGHTS – FRIDAY, OCTOBER 28 EDITION

October 28, 2022

…us placebo with tolebrutinib 60 mg after 12 weeks of active treatment. Long-term data are now available. At the end of the 16-week trial there was a treatment gap (0-21 weeks) before starting the long-term extension (Reich et al. ECTRIMS 2022; P297). In Part A, patients received the original study dose (5-60 mg/day); at 48 weeks (Part B), all patients received the 60-mg dose. In the continuous 60-mg group, the mean number of Gd+ lesions, new/enlar…

ECTRIMS 2022 HIGHLIGHTS – THURSDAY, OCTOBER 27 EDITION

October 27, 2022

…S 2022. October 29 Edition October 28 Edition Does COVID-19 worsen MS? Long-term DMT data MS risk with adolescent obesity Is vitamin D supplementation effective? Poor vaccine response in children Hypogammaglobulinemia with ocrelizumab Effect of ibudilast on SELs Clinical tip of the day CONGRESS HIGHLIGHTS – THURSDAY EDITION Does COVID-19 worsen MS? There are conflicting reports on whether MS worsens following COVID-19 infection. An analysis of the…